Switch to:

GuruFocus Financial Strength Rank measures how strong a company’s financial situation is. It is based on these factors

1. The debt burden that the company has as measured by its Interest coverage (current year).
2. Debt to revenue ratio. The lower, the better
3. Altman Z-score.

A company ranks high with financial strength is likely to withstand any business slowdowns and recessions.

Financial Strength : 7/10

vs
industry
vs
history
Cash to Debt 5.97
NAS:SGNT's Cash to Debt is ranked higher than
55% of the 778 Companies
in the Global Drug Manufacturers - Specialty & Generic industry.

( Industry Median: 3.15 vs. NAS:SGNT: 5.97 )
Ranked among companies with meaningful Cash to Debt only.
NAS:SGNT' s Cash to Debt Range Over the Past 10 Years
Min: 0.96  Med: 28.34 Max: No Debt
Current: 5.97
Equity to Asset 0.71
NAS:SGNT's Equity to Asset is ranked higher than
63% of the 671 Companies
in the Global Drug Manufacturers - Specialty & Generic industry.

( Industry Median: 0.63 vs. NAS:SGNT: 0.71 )
Ranked among companies with meaningful Equity to Asset only.
NAS:SGNT' s Equity to Asset Range Over the Past 10 Years
Min: -1.15  Med: 0.73 Max: 0.82
Current: 0.71
-1.15
0.82
F-Score: 2
Z-Score: 4.36
M-Score: -2.35
GuruFocus Profitability Rank ranks how profitable a company is and how likely the company’s business will stay that way. It is based on these factors:

1. Operating Margin
2. Trend of the Operating Margin (5-year average). The company with an uptrend profit margin has a higher rank.
••3. Consistency of the profitability
4. Piotroski F-Score
5. Predictability Rank•

The maximum rank is 10. A rank of 7 or higher means a higher profitability and may stay that way. A rank of 3 or lower indicates that the company has had trouble to make a profit.

Profitability Rank is not directly related to the Financial Strength Rank. But if a company is consistently profitable, its financial strength will be stronger.

Profitability & Growth : 1/10

vs
industry
vs
history
Operating margin (%) -17.87
NAS:SGNT's Operating margin (%) is ranked lower than
82% of the 724 Companies
in the Global Drug Manufacturers - Specialty & Generic industry.

( Industry Median: 8.44 vs. NAS:SGNT: -17.87 )
Ranked among companies with meaningful Operating margin (%) only.
NAS:SGNT' s Operating margin (%) Range Over the Past 10 Years
Min: -258.05  Med: -14.11 Max: 12.82
Current: -17.87
-258.05
12.82
Net-margin (%) -8.47
NAS:SGNT's Net-margin (%) is ranked lower than
78% of the 726 Companies
in the Global Drug Manufacturers - Specialty & Generic industry.

( Industry Median: 5.90 vs. NAS:SGNT: -8.47 )
Ranked among companies with meaningful Net-margin (%) only.
NAS:SGNT' s Net-margin (%) Range Over the Past 10 Years
Min: -253.66  Med: -13.25 Max: 12.79
Current: -8.47
-253.66
12.79
ROE (%) -9.63
NAS:SGNT's ROE (%) is ranked lower than
76% of the 753 Companies
in the Global Drug Manufacturers - Specialty & Generic industry.

( Industry Median: 6.76 vs. NAS:SGNT: -9.63 )
Ranked among companies with meaningful ROE (%) only.
NAS:SGNT' s ROE (%) Range Over the Past 10 Years
Min: -26.08  Med: -8.34 Max: 16.09
Current: -9.63
-26.08
16.09
ROA (%) -7.02
NAS:SGNT's ROA (%) is ranked lower than
76% of the 783 Companies
in the Global Drug Manufacturers - Specialty & Generic industry.

( Industry Median: 3.54 vs. NAS:SGNT: -7.02 )
Ranked among companies with meaningful ROA (%) only.
NAS:SGNT' s ROA (%) Range Over the Past 10 Years
Min: -59.67  Med: -11.75 Max: 12.27
Current: -7.02
-59.67
12.27
ROC (Joel Greenblatt) (%) -50.10
NAS:SGNT's ROC (Joel Greenblatt) (%) is ranked lower than
80% of the 776 Companies
in the Global Drug Manufacturers - Specialty & Generic industry.

( Industry Median: 14.07 vs. NAS:SGNT: -50.10 )
Ranked among companies with meaningful ROC (Joel Greenblatt) (%) only.
NAS:SGNT' s ROC (Joel Greenblatt) (%) Range Over the Past 10 Years
Min: -3410.41  Med: -74.24 Max: 49.31
Current: -50.1
-3410.41
49.31
Revenue Growth (3Y)(%) 14.40
NAS:SGNT's Revenue Growth (3Y)(%) is ranked higher than
75% of the 604 Companies
in the Global Drug Manufacturers - Specialty & Generic industry.

( Industry Median: 5.60 vs. NAS:SGNT: 14.40 )
Ranked among companies with meaningful Revenue Growth (3Y)(%) only.
NAS:SGNT' s Revenue Growth (3Y)(%) Range Over the Past 10 Years
Min: 0  Med: 5.2 Max: 46.4
Current: 14.4
0
46.4
EBITDA Growth (3Y)(%) 42.20
NAS:SGNT's EBITDA Growth (3Y)(%) is ranked higher than
86% of the 564 Companies
in the Global Drug Manufacturers - Specialty & Generic industry.

( Industry Median: 9.30 vs. NAS:SGNT: 42.20 )
Ranked among companies with meaningful EBITDA Growth (3Y)(%) only.
NAS:SGNT' s EBITDA Growth (3Y)(%) Range Over the Past 10 Years
Min: 0  Med: -43.7 Max: 42.2
Current: 42.2
0
42.2
EPS Growth (3Y)(%) 3.70
NAS:SGNT's EPS Growth (3Y)(%) is ranked lower than
57% of the 529 Companies
in the Global Drug Manufacturers - Specialty & Generic industry.

( Industry Median: 6.70 vs. NAS:SGNT: 3.70 )
Ranked among companies with meaningful EPS Growth (3Y)(%) only.
NAS:SGNT' s EPS Growth (3Y)(%) Range Over the Past 10 Years
Min: 0  Med: -35.1 Max: 3.7
Current: 3.7
0
3.7
» NAS:SGNT's 10-Y Financials

Financials


Revenue & Net Income
Cash & Debt
Oprt. Cash Flow & Free Cash Flow
Oprt. Cash Flow & Net Income

» Details

Guru Trades

Q3 2015

SGNT Guru Trades in Q3 2015

Jim Simons Sold Out
George Soros Sold Out
Paul Tudor Jones Sold Out
Steven Cohen 229,500 sh (-6.29%)
» More
Q4 2015

SGNT Guru Trades in Q4 2015

Paul Tudor Jones 25,829 sh (New)
Steven Cohen 191,600 sh (-16.51%)
» More
Q1 2016

SGNT Guru Trades in Q1 2016

Steven Cohen 118,100 sh (-38.36%)
Paul Tudor Jones 11,664 sh (-54.84%)
» More
Q2 2016

SGNT Guru Trades in Q2 2016

NWQ Managers 1,243,252 sh (New)
Paul Tudor Jones Sold Out
Steven Cohen Sold Out
» More
» Details

Insider Trades

Latest Guru Trades with SGNT

(List those with share number changes of more than 20%, or impact to portfolio more than 0.1%)

No Entry found in the selected group of Gurus. You can
  • 1. Modify your Personalized List of Gurus, or
  • 2. Click on Premium Premium Tools above to check out all the Gurus, or
  • 3. Click on Premium Plus Premium Plus above for the stocks picks of all the institutional investment advisors (>4000)
» Interactive Charts

Peter Lynch Chart ( What is Peter Lynch Charts )

Business Description

Industry: Drug Manufacturers » Drug Manufacturers - Specialty & Generic
Compare:NAS:HRTX, OTCPK:EVOTF, OTCPK:LPCUF, NAS:SCMP, NAS:MNTA, NAS:ACET, NAS:SCLN, NAS:AMPH, NAS:FLXN, NAS:LBIO, OTCPK:KHTRF, NAS:SGYP, NAS:EGRX, NAS:ADMS, NAS:COLL, NAS:ARLZ, NAS:KPTI, NYSE:LCI, NAS:RIGL, OTCPK:TWMJF » details
Sagent Pharmaceuticals Inc is a specialty pharmaceutical company. The Company is engaged in developing, manufacturing, sourcing and marketing injectable pharmaceutical products which it sells in the United States of America.

Sagent Pharmaceuticals Inc is a Delaware corporation that was incorporated in 2011. The Company was initially founded in 2006 as Sagent Holding Co., a Cayman Islands company, it reincorporated as Sagent Pharmaceuticals, Inc., a Delaware corporation, in connection with its initial public offering, on April 26, 2011. The Company is engaged in the developing, manufacturing, sourcing and marketing injectable pharmaceutical products, which it sells primarily in the United States of America. The Company primarily focuses on generic injectable pharmaceuticals, which provide customers a lower-cost alternative to branded products when applicable patents have expired or been declared invalid, or when the products are determined not to infringe the patents of others, it offers customers, products across anti-infective, oncolytic and critical care indications in a variety of presentations, including single- and multi-dose vials and ready-to-use pre-filled syringes and premix bags. It generally seeks to develop injectable products where the form or packaging of the product can be enhanced to improve delivery, product safety or end-user convenience. At the year end, the Company's product portfolio has grown to a total of 53 products which can be classified into the following three product categories: anti-infective, oncology and critical care. Its anti-infective products assist in the treatment of various infections and related symptoms, its oncology products are used in the treatment of cancer and cancer-related medical problems, and its critical care products are used in a variety of critical care applications and include anesthetics, cardiac medications, steroidal products and sedatives. The Company distributes its products primarily through pharmaceutical wholesalers and, to a lesser extent, specialty distributors that focus on particular therapeutic product categories, for use by a wide variety of end-users, including U.S. hospitals, integrated delivery networks and alternative site facilities. The Company's principal competitors include Fresenius Kabi, a division of Fresenius SE, Hospira, Inc., Pfizer Inc., Sandoz International GmbH, a division of Novartis AG, Teva Pharmaceutical Industries Ltd. and West-Ward Pharmaceutical Corp. The Company is subject to extensive regulation by governmental authorities in the U.S. and in other countries.

Ratios

vs
industry
vs
history
Forward P/E 46.73
SGNT's Forward P/E is ranked lower than
93% of the 69 Companies
in the Global Drug Manufacturers - Specialty & Generic industry.

( Industry Median: 17.76 vs. SGNT: 46.73 )
Ranked among companies with meaningful Forward P/E only.
N/A
P/B 2.82
SGNT's P/B is ranked higher than
54% of the 699 Companies
in the Global Drug Manufacturers - Specialty & Generic industry.

( Industry Median: 3.08 vs. SGNT: 2.82 )
Ranked among companies with meaningful P/B only.
SGNT' s P/B Range Over the Past 10 Years
Min: 1.4  Med: 3.21 Max: 5.06
Current: 2.82
1.4
5.06
P/S 2.39
SGNT's P/S is ranked higher than
57% of the 695 Companies
in the Global Drug Manufacturers - Specialty & Generic industry.

( Industry Median: 2.86 vs. SGNT: 2.39 )
Ranked among companies with meaningful P/S only.
SGNT' s P/S Range Over the Past 10 Years
Min: 0.46  Med: 2.41 Max: 3.86
Current: 2.39
0.46
3.86
Current Ratio 2.16
SGNT's Current Ratio is ranked lower than
56% of the 678 Companies
in the Global Drug Manufacturers - Specialty & Generic industry.

( Industry Median: 2.47 vs. SGNT: 2.16 )
Ranked among companies with meaningful Current Ratio only.
SGNT' s Current Ratio Range Over the Past 10 Years
Min: 1.57  Med: 3.1 Max: 4.65
Current: 2.16
1.57
4.65
Quick Ratio 1.15
SGNT's Quick Ratio is ranked lower than
71% of the 678 Companies
in the Global Drug Manufacturers - Specialty & Generic industry.

( Industry Median: 1.81 vs. SGNT: 1.15 )
Ranked among companies with meaningful Quick Ratio only.
SGNT' s Quick Ratio Range Over the Past 10 Years
Min: 0.89  Med: 2.17 Max: 3.74
Current: 1.15
0.89
3.74
Days Inventory 133.13
SGNT's Days Inventory is ranked lower than
59% of the 679 Companies
in the Global Drug Manufacturers - Specialty & Generic industry.

( Industry Median: 115.00 vs. SGNT: 133.13 )
Ranked among companies with meaningful Days Inventory only.
SGNT' s Days Inventory Range Over the Past 10 Years
Min: 97.42  Med: 107.72 Max: 198.67
Current: 133.13
97.42
198.67
Days Sales Outstanding 61.41
SGNT's Days Sales Outstanding is ranked higher than
64% of the 579 Companies
in the Global Drug Manufacturers - Specialty & Generic industry.

( Industry Median: 77.08 vs. SGNT: 61.41 )
Ranked among companies with meaningful Days Sales Outstanding only.
SGNT' s Days Sales Outstanding Range Over the Past 10 Years
Min: 6.35  Med: 60.9 Max: 93.34
Current: 61.41
6.35
93.34
Days Payable 82.15
SGNT's Days Payable is ranked higher than
61% of the 526 Companies
in the Global Drug Manufacturers - Specialty & Generic industry.

( Industry Median: 67.81 vs. SGNT: 82.15 )
Ranked among companies with meaningful Days Payable only.
SGNT' s Days Payable Range Over the Past 10 Years
Min: 52.21  Med: 82.95 Max: 275.84
Current: 82.15
52.21
275.84

Buy Back

vs
industry
vs
history
3-Year Average Share Buyback Ratio -5.30
SGNT's 3-Year Average Share Buyback Ratio is ranked lower than
54% of the 432 Companies
in the Global Drug Manufacturers - Specialty & Generic industry.

( Industry Median: -4.80 vs. SGNT: -5.30 )
Ranked among companies with meaningful 3-Year Average Share Buyback Ratio only.
SGNT' s 3-Year Average Share Buyback Ratio Range Over the Past 10 Years
Min: -153.3  Med: -5.3 Max: 0
Current: -5.3
-153.3
0

Valuation & Return

vs
industry
vs
history
Price/Net Current Asset Value 8.95
SGNT's Price/Net Current Asset Value is ranked lower than
57% of the 441 Companies
in the Global Drug Manufacturers - Specialty & Generic industry.

( Industry Median: 7.54 vs. SGNT: 8.95 )
Ranked among companies with meaningful Price/Net Current Asset Value only.
SGNT' s Price/Net Current Asset Value Range Over the Past 10 Years
Min: 4.01  Med: 5 Max: 10
Current: 8.95
4.01
10
Price/Tangible Book 4.22
SGNT's Price/Tangible Book is ranked lower than
53% of the 645 Companies
in the Global Drug Manufacturers - Specialty & Generic industry.

( Industry Median: 3.80 vs. SGNT: 4.22 )
Ranked among companies with meaningful Price/Tangible Book only.
SGNT' s Price/Tangible Book Range Over the Past 10 Years
Min: 2.36  Med: 3.64 Max: 4.99
Current: 4.22
2.36
4.99
Price/Projected FCF 5.13
SGNT's Price/Projected FCF is ranked lower than
67% of the 287 Companies
in the Global Drug Manufacturers - Specialty & Generic industry.

( Industry Median: 2.65 vs. SGNT: 5.13 )
Ranked among companies with meaningful Price/Projected FCF only.
SGNT' s Price/Projected FCF Range Over the Past 10 Years
Min: 2.98  Med: 3.57 Max: 5.13
Current: 5.13
2.98
5.13
Price/Median PS Value 0.99
SGNT's Price/Median PS Value is ranked higher than
67% of the 637 Companies
in the Global Drug Manufacturers - Specialty & Generic industry.

( Industry Median: 1.16 vs. SGNT: 0.99 )
Ranked among companies with meaningful Price/Median PS Value only.
SGNT' s Price/Median PS Value Range Over the Past 10 Years
Min: 0.24  Med: 1.04 Max: 1.53
Current: 0.99
0.24
1.53
Earnings Yield (Greenblatt) (%) -7.60
SGNT's Earnings Yield (Greenblatt) (%) is ranked lower than
83% of the 752 Companies
in the Global Drug Manufacturers - Specialty & Generic industry.

( Industry Median: 2.90 vs. SGNT: -7.60 )
Ranked among companies with meaningful Earnings Yield (Greenblatt) (%) only.
SGNT' s Earnings Yield (Greenblatt) (%) Range Over the Past 10 Years
Min: -7.6  Med: 1.7 Max: 7.5
Current: -7.6
-7.6
7.5

More Statistics

Revenue (TTM) (Mil) $297.8
EPS (TTM) $ -0.77
Short Percentage of Float4.75%
52-Week Range $10.55 - 21.88
Shares Outstanding (Mil)32.91

Analyst Estimate

Dec16 Dec17 Dec18
Revenue (Mil $) 338 379 412
EPS ($) 0.47 0.73 0.97
EPS w/o NRI ($) 0.47 0.73 0.97
EPS Growth Rate
(3Y to 5Y Estimate)
N/A
Dividends Per Share ($)
» More Articles for NAS:SGNT

Headlines

Articles On GuruFocus.com
NWQ Bought 12 New Holdings in 2nd Quarter Sep 16 2016 

More From Other Websites
NWQ Bought 12 New Holdings in 2nd Quarter Sep 16 2016
SAGENT PHARMACEUTICALS, INC. Files SEC form 8-K, Completion of Acquisition or Disposition of Assets,... Aug 29 2016
Nichi-Iko Pharmaceutical Co., Ltd. Announces Results of Tender Offer to Purchase All of the... Aug 29 2016
Nichi-Iko Pharmaceutical Co., Ltd. Announces Results of Tender Offer to Purchase All of the... Aug 29 2016
Chemical Financial Set to Join S&P MidCap 400; Supervalu, Shoe Carnival and Eagle Pharmaceuticals to... Aug 22 2016
Sagent Pharmaceuticals Initiates a Nationwide Voluntary Recall of Oxacillin for Injection, USP, 10 g... Aug 17 2016
Sagent Pharmaceuticals Initiates a Nationwide Voluntary Recall of Oxacillin for Injection, USP, 10 g... Aug 17 2016
SAGENT PHARMACEUTICALS, INC. Financials Aug 16 2016
ETF’s with exposure to Sagent Pharmaceuticals, Inc. : August 12, 2016 Aug 12 2016
Gainey McKenna & Egleston Announces A Class Action Lawsuit Has Been Filed Against Sagent... Aug 10 2016
Sagent Pharmaceuticals, Inc. :SGNT-US: Earnings Analysis: Q2, 2016 By the Numbers : August 10, 2016 Aug 10 2016
Nichi-Iko Pharmaceutical Co., Ltd. Announces Expiration of HSR Waiting Period for Proposed... Aug 09 2016
Nichi-Iko Pharmaceutical Co., Ltd. Announces Expiration of HSR Waiting Period for Proposed... Aug 09 2016
Changing Landscape for Generic-Drug Makers Creates Opportunities Aug 08 2016
SAGENT PHARMACEUTICALS, INC. Files SEC form 10-Q, Quarterly Report Aug 05 2016
What Awaits MNK & Other Drug Stocks this Earnings Season? Aug 01 2016
Shepard Vision, Inc., a Wholly-Owned Subsidiary of Nichi-Iko Pharmaceutical Co., Ltd, Commences... Aug 01 2016
Shepard Vision, Inc., a Wholly-Owned Subsidiary of Nichi-Iko Pharmaceutical Co., Ltd, Commences... Aug 01 2016
Sapiens Names Andre M. Boisvert Chairman of Sapiens DECISION Board of Directors Jul 28 2016
Sapiens Names Andre M. Boisvert Chairman of Sapiens DECISION Board of Directors Jul 28 2016

Personalized Checklist

Checklist has been moved to "Checklist" tab.

Get WordPress Plugins for easy affiliate links on Stock Tickers and Guru Names | Earn affiliate commissions by embedding GuruFocus Charts
GuruFocus Affiliate Program: Earn up to $400 per referral. ( Learn More)